Log in

Best Stocks Under $30.00 for 2020

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $30.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $30.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $30.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Telephone and Data Systems logo

#1 - Telephone and Data Systems

NYSE:TDS
Stock Price: $19.84 (+$0.27)
PE Ratio: 14.17
Market Cap: $4.25 billion
P/E Ratio: 14.2
Dividend Yield: 3.47 %
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $31.70 (59.8% Upside)
Telephone and Data Systems, Inc., a telecommunications company, provides communications services in the United States. It operates through three segments: U.S. Cellular, Wireline, and Cable. The company offers cellular services to postpaid and prepaid customers, including retail consumers, government entities, and business customers located in its service territories; national plans with voice, messaging, and data usage options; and advanced wireless solutions, such as machine-to-machine solution and software applications for various categories of monitor and control, business automation/operations, communication, and asset management. It also provides wireless devices comprising handsets, tablets, mobile hotspots, home phones, and routers; and accessories that include wireless essentials, which comprise cases, screen protectors, chargers, and memory cards, as well as various consumer electronics, such as headphones, smart speakers, wearables, and home automation products. In addition, the company offers wireline services to residential customers comprising broadband and digital television video services, as well as voice services, such as local and long-distance telephone, voice over Internet protocol (VoIP), find me follow me, collaboration, instant messaging, and other services; broadband, IP-based, and hosted voice and collaboration services to small- and medium-sized businesses; and wireline services to traditional interexchange and wireless carriers. Further, it provides business services, including data networking, Ethernet, broadband access, and VoIP services to small- and medium-sized businesses, as well as operates 262 retail stores and kiosks. The company offers its services to approximately 6 million connections. It sells its products through retail sales, direct sales, third-party retailers, and independent agents, as well as through website and telesales. The company was incorporated in 1968 and is headquartered in Chicago, Illinois.
i3 Verticals logo

#2 - i3 Verticals

NASDAQ:IIIV
Stock Price: $27.88 (+$0.38)
PE Ratio: -557.60
Market Cap: $766.31 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $34.20 (22.7% Upside)
i3 Verticals, Inc. provides integrated payment and software solutions to small- and medium-sized businesses and organizations in education, non-profit, public sector, property management, and healthcare markets in the United States. It operates in two segments, Merchant Services and Proprietary Software and Payments. The company offers payment processing services, including merchant onboarding, risk and underwriting, authorization, settlement, chargeback processing, and other merchant support. Its payment processing services enable clients to accept electronic payments, facilitating the exchange of funds and transaction data between clients, financial institutions, and payment networks. The company also licenses software; and provides ongoing support, and other point of sale-related solutions. It offers its solutions to its clients through direct sales force, as well as through a network of distribution partners, including independent software vendors, value-added resellers, independent sales organizations, and other referral partners, such as financial institutions. The company was founded in 2012 and is headquartered in Nashville, Tennessee.
Tarsus Pharmaceuticals logo

#3 - Tarsus Pharmaceuticals

NASDAQ:TARS
Stock Price: $22.38 (+$2.48)
Market Cap: $431.02 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $37.25 (66.4% Upside)
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Barings BDC logo

#4 - Barings BDC

NYSE:BBDC
Stock Price: $8.75 (+$0.03)
PE Ratio: -218.75
Market Cap: $419.67 million
Dividend Yield: 7.80 %
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.81 (0.7% Upside)
Barings BDC, Inc. (NYSE: BBDC) is a publicly traded, externally managed investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. Barings BDC seeks to invest primarily in senior secured loans to private U.S. middle-market companies that operate across a wide range of industries. It specializes in mezzanine, leveraged buyouts, management buyouts, ESOPs, change of control transactions, acquisition financings, growth financing, and recapitalizations in lower middle market, mature, and later stage companies. Barings BDC's investment activities are managed by its investment adviser, Barings LLC, a leading global asset manager based in Charlotte, NC with over $335 billion of AUM firm-wide. For more information, visit www.baringsbdc.com.
Everi logo

#5 - Everi

NYSE:EVRI
Stock Price: $11.15 (+$0.30)
PE Ratio: -10.93
Market Cap: $958.10 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.67 (4.6% Upside)
Everi Holdings Inc. provides entertainment and technology solutions for the casino, interactive, and gaming industries in the United States, Europe, Canada, the Caribbean, Central America, and Asia. It operates in two segments, Games and FinTech. The company offers local and wide-area progressive gaming products, such as classic mechanical reel games, video reel games, Empire 5527, Empire Flex, Empire DCX, Empire MPX, Core HDX, and the Texan HDX; TournEvent, a slot tournament terminal and system machine; and sells player terminals, licenses, back office systems, and other related equipment. It also provides cash access services, such as ATM cash withdrawals, POS debit card cash access transactions, and credit card cash access transactions; check verification and warranty services; CashClub, a software payments platform that provides gaming establishments with a personal computer workstation software user interface and point-of-sale terminal; fully integrated kiosks that provide multiple functions to the casino floor; and other integrated kiosk solutions. In addition, the company offers non-ATM terminals that perform authorizations for credit card cash access and POS debit card transactions; database services; and an online payment processing solution for gaming operators in states that offer intra-state and Internet-based gaming and lottery activities. Further, it provides Everi Compliance solutions to assist casino operators with meeting regulatory requirements; Central Credit, a gaming patron credit bureau service; JackpotXpress, a jackpot payout and tax form management platform; player loyalty platform; and EveriCares for socially conscious ticket redemption. The company was formerly known as Global Cash Access Holdings, Inc. and changed its name to Everi Holdings Inc. in August 2015. Everi Holdings Inc. was founded in 1998 and is headquartered in Las Vegas, Nevada.
Mirum Pharmaceuticals logo

#6 - Mirum Pharmaceuticals

NASDAQ:MIRM
Stock Price: $22.25 (+$0.51)
PE Ratio: -6.51
Market Cap: $572.20 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $40.60 (82.5% Upside)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.
Interfor logo

#7 - Interfor

OTCMKTS:IFSPF
Stock Price: $15.04
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $22.08 (46.8% Upside)
Interfor Corporation, together with its subsidiaries, produces and sells wood products in Canada, the United States, Japan, China, Hong Knog, Taiwan, and internationally. It offers wooden products for appearance timbers, decking, fascia and trims, framings, furniture, industrial packaging, Japan zairai, millworks, paneling, sidings, trusses, and windows and doors. The company was formerly known as International Forest Products Limited and changed its name to Interfor Corporation in May 2014. Interfor Corporation was founded in 1963 and is headquartered in Vancouver, Canada.
Teranga Gold logo

#8 - Teranga Gold

OTCMKTS:TGCDF
Stock Price: $10.54 (+$0.01)
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $17.75 (68.4% Upside)
Teranga Gold Corporation engages in the exploration, development, production, and sale of gold in West Africa. The company's flagship project is the Sabodala gold mine covering an area of 291 square kilometers mine license and 629 square kilometers exploration land package located in the Republic of Senegal. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
Tourmaline Oil logo

#9 - Tourmaline Oil

OTCMKTS:TRMLF
Stock Price: $14.23 (-$0.03)
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $25.79 (81.2% Upside)
Tourmaline Oil Corp. acquires, explores for, develops, and produces oil and natural gas properties in the Western Canadian Sedimentary Basin. It holds interests in properties located in the Alberta Deep Basin, Northeast British Columbia Montney, and the Peace River High Triassic oil complex. The company was founded in 2008 and is headquartered in Calgary, Canada.
NGM Biopharmaceuticals logo

#10 - NGM Biopharmaceuticals

NYSE:NGM
Stock Price: $23.85 (+$1.07)
Market Cap: $1.65 billion
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $31.38 (31.6% Upside)
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
89bio logo

#11 - 89bio

NASDAQ:ETNB
Stock Price: $27.28 (+$0.24)
PE Ratio: -0.78
Market Cap: $542.30 million
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $58.38 (114.0% Upside)
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Viking Therapeutics logo

#12 - Viking Therapeutics

NASDAQ:VKTX
Stock Price: $6.68 (+$0.32)
PE Ratio: -15.18
Market Cap: $487.32 million
Consensus Rating: Buy (11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.56 (147.8% Upside)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
CymaBay Therapeutics logo

#13 - CymaBay Therapeutics

NASDAQ:CBAY
Stock Price: $7.46 (+$0.20)
PE Ratio: -7.94
Market Cap: $513.90 million
Consensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.27 (77.9% Upside)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Enterprise Products Partners logo

#14 - Enterprise Products Partners

NYSE:EPD
Stock Price: $19.93 (-$0.43)
PE Ratio: 9.67
Market Cap: $43.50 billion
P/E Ratio: 9.7
Dividend Yield: 8.74 %
Consensus Rating: Buy (13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $24.75 (24.2% Upside)
Enterprise Products Partners L.P. provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals, and refined products. The company operates through four segments: NGL Pipelines & Services, Crude Oil Pipelines & Services, Natural Gas Pipelines & Services, and Petrochemical & Refined Products Services. The NGL Pipelines & Services segment offers natural gas processing and related NGL marketing services. It operates approximately 19,900 miles of NGL pipelines; NGL and related product storage facilities; 16 NGL fractionators; 22 natural gas processing facilities; and liquefied petroleum gas and ethane export terminals, and related operations. The Crude Oil Pipelines & Services segment operates approximately 5,300 miles of crude oil pipelines; and crude oil storage and marine terminals located in Oklahoma, New Mexico, and Texas, as well as a fleet of 310 tractor-trailer tank trucks used to transport crude oil. It also engages in crude oil marketing activities. The Natural Gas Pipelines & Services segment operates approximately 19,400 miles of natural gas pipeline systems to gather, treat, and transport natural gas in Colorado, Louisiana, New Mexico, Texas, and Wyoming. It is also involved in natural gas marketing activities. The Petrochemical & Refined Products Services segment operates propylene production facilities; butane isomerization complex and related deisobutanizer units; isobutane dehydrogenation, octane enhancement, and high purity isobutylene production facilities; refined products pipelines aggregating approximately 3,300 miles, terminals, and associated marketing activities; ethylene export terminal and related operations; and marine transportation. The company was founded in 1968 and is headquartered in Houston, Texas.
Change Healthcare logo

#15 - Change Healthcare

NASDAQ:CHNG
Stock Price: $17.65 (+$0.44)
PE Ratio: -32.09
Market Cap: $5.37 billion
Consensus Rating: Buy (14 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $18.50 (4.8% Upside)
Change Healthcare Inc., an independent healthcare technology platform, provides data and analytics-driven solutions to enhance clinical, financial, administrative, and patient engagement outcomes in the United States healthcare system. It operates through three segments: Software and Analytics, Network Solutions, and Technology-Enabled Services. The Software and Analytics segment offers software and analytics solutions for financial performance, payment accuracy, clinical decision management, value-based payment, provider and consumer engagement, and imaging and clinical workflow. The Network Solutions segment enables financial, administrative, and clinical transactions; electronic business-to-business and consumer-to-business payments; and aggregation and analytics of clinical and financial data. The Technology-Enabled Services segment provides solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration, and healthcare consulting. The company was founded in 2016 and is headquartered in Nashville, Tennessee.
Rackspace Technology logo

#16 - Rackspace Technology

NASDAQ:RXT
Stock Price: $17.70 (+$0.62)
Market Cap: $3.55 billion
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $27.89 (57.6% Upside)
Rackspace Technology, Inc. operates as a multi cloud technology services company worldwide. It operates through Multicloud Services and Apps & Cross Platform segments. The Multicloud Services segment provides public and private cloud managed services, which allow customers to determine, manage, and optimize the right infrastructure, platforms, and services; and professional services related to designing and building multi cloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security, and data services, as well as professional services related to designing and implementing application, security, and data services. The company serves automotive, digital agencies, education, energy, financial services, gaming, government, healthcare, manufacturing, media and entertainment, non-profit, retail, and public sectors. Rackspace Technology, Inc. was founded in 1998 and is headquartered in San Antonio, Texas.
Immunic logo

#17 - Immunic

NASDAQ:IMUX
Stock Price: $17.55 (+$0.17)
PE Ratio: -5.95
Market Cap: $363.60 million
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $58.86 (235.4% Upside)
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in Phase 2 trial to treat Crohn's disease. The company is also developing IMU-935, an inverse agonist of RORgt; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
SSR Mining logo

#18 - SSR Mining

NASDAQ:SSRM
Stock Price: $17.65 (-$0.10)
PE Ratio: 37.55
Market Cap: $2.18 billion
P/E Ratio: 37.6
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $32.32 (83.1% Upside)
SSR Mining Inc., a resource company, engages in the acquisition, exploration, development, and operation of precious metal resource properties in the Americas. The company primarily explores for gold and silver deposits. Its projects include the Marigold mine located in southeastern Humboldt County, Nevada, the United States; the Seabee Gold Operation located in Saskatchewan, Canada; and the Puna Operations in Jujuy, Argentina. The company was formerly known as Silver Standard Resources Inc. and changed its name to SSR Mining Inc. in August 2017. SSR Mining Inc. was founded in 1946 and is headquartered in Vancouver, Canada.
PDC Energy logo

#19 - PDC Energy

NASDAQ:PDCE
Stock Price: $18.06 (-$0.39)
PE Ratio: -2.49
Market Cap: $1.80 billion
Consensus Rating: Buy (14 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $22.92 (26.9% Upside)
PDC Energy, Inc., an independent exploration and production company, acquires, explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the United States. The company's operations are primarily located in the Wattenberg Field in Colorado and the Delaware Basin in Texas. As of December 31, 2019, it owned interests in approximately 2,649 productive gross wells. The company was formerly known as Petroleum Development Corporation and changed its name to PDC Energy, Inc. in June 2012. PDC Energy, Inc. was founded in 1969 and is headquartered in Denver, Colorado.
Kiniksa Pharmaceuticals logo

#20 - Kiniksa Pharmaceuticals

NASDAQ:KNSA
Stock Price: $18.26 (+$0.56)
PE Ratio: -7.70
Market Cap: $1.24 billion
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $33.75 (84.8% Upside)
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.